Identification of tumor neoantigens during immune checkpoint blockade in resectable non-small cell lung cancer


Identification of tumor neoantigens during immune checkpoint blockade in resectable non-small cell lung cancer

You are being asked to participate in this study because you have non-small cell lung cancer and you have had surgery to remove your lung tumor. People who have lung cancer and undergo surgery still have a significant risk of their cancer returning outside of the lung. The purpose of this study is to determine if a new type of immune-based therapy can increase your chance of being cured. Chemotherapy is usually given after surgery to reduce the risk of the cancer returning. Despite aggressive surgery and chemotherapy, the risk of lung cancer recurrence remains high in most patients. This study aims to determine if a novel immune therapy consisting of two drugs is feasible and potentially increases the chance of cure in lung cancer patients after surgery and standard chemotherapy. The immune-based therapy being given in this study consists of two medications named durvalumab and tremelimumab. These medications are both given intravenously once every four weeks. The medications being given in this study has previously been tested in patients with more advanced cancer. These studies have demonstrated that the immune-based therapy with durvalumab and tremelimumab can be given safely to patients with manageable side-effects. Approximately 30 individuals will be asked to participate in this study.

Are you Eligible? (Inclusion Criteria)

1) Patients must be completely recovered from surgery and have received adjuvant
+/- radiation therapy (PORT) as determined by the treating physician
2) Study treatment must begin within 30 days of surgical resection or adjuvant
treatment. This
timeline may be extended if further time for recovery from treatment related
toxicities is required
3) No previous treatment with a PD1 or PD-L1 inhibitor, including durvalumab or
an anti-CTLA4,
including tremelimumab
4) Histologically or cytologically confirmed NSCLC (Stage IB-IIIA)

Specialty Area(s)


Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States